US FDA Learns 'Lessons Of History,' Takes Opioid Fight To Gabapentinoids
Agency investigating potential misuse and abuse of gabapentinoids, which CDC had recommended as alternative to opioids, in latest twist to epidemic.
You may also be interested in...
FDA advisory committee members raise concerns about inappropriate marketing and prescribing practices.
Mandatory training could be reserved for physicians who want to prescribe opioids for longer-term use, as opposed to those who would prescribe recommended amounts in blister packs; evidence that blister packs would affect prescribing still is needed, however.
Part D plans would need expanded point-of-sale 'edits' for high-dose prescriptions and supply limits for patients new to opioids under proposal in 2019 'call letter' for the Medicare pharmacy benefit.